Literature DB >> 28131170

Longitudinally extensive transverse myelitis immune-mediated in aquaporin-4 antibody negative patients: Disease heterogeneity.

Edgar Carnero Contentti1, Javier Pablo Hryb2, Sergio Morales2, Alejandra Gomez2, Edson Chiganer3, José Luis Di Pace2, Carmen Lessa3, Mónica Perassolo2.   

Abstract

BACKGROUND: Longitudinally extensive transverse myelitis (LETM) is a frequent manifestation of neuromyelitis optica spectrum disorder (NMOSD). However, it can also occur in other immune-mediated diseases of the central nervous system (CNS). Positive aquoporin-4 antibodies (AQP4-ab) predict higher relapse rate after LETM.
OBJECTIVE: To assess clinical and brain/spinal cord magnetic resonance imaging (MRI) features of LETM immune-mediated at onset and to compare AQP4-ab negative (N-LETM) with AQP4-ab positive (P-LETM) patients.
METHODS: Thirty LETM patients remitted for consideration of inflammatory CNS diseases were included. Demographics, clinical, serological, disability and neuroimaging features at onset we reviewed retrospectively and divided into two groups according to serological status. AQP4-ab were tested using indirect immunofluorescence.
RESULTS: Twenty-one patients were N-LETM. We did not find significant differences between both groups as regards gender, age at onset, dysfunction (motor, sensory, bladder/bowel) or disability. However, recurrences (p=0.04) of myelitis and number of relapses (p=0.03) were associated to P-LETM. N-LETM was associated with normal brain MRI (p=0.04) at onset. AQP4-ab positive were only observed in NMOSD patients. N-LETM (24%) and P-LETM (56%) patients had relapses of optic neuritis (ON) during the follow-up.
CONCLUSION: LETM at onset is a heterogeneous syndrome with similar clinical and neuroimaging features between both groups. N-LETM displayed a lower relapse rate of myelitis and ON.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aquaporin-4 antibodies; Longitudinally extensive transverse myelitis; Multiple sclerosis; Neuromyelitis optica spectrum disorders

Mesh:

Substances:

Year:  2016        PMID: 28131170     DOI: 10.1016/j.jns.2016.12.033

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset.

Authors:  Dena Sadeghi-Bahmani; Mahdi Barzegar; Omid Mirmosayyeb; Saeed Vaheb; Nasim Nehzat; Vahid Shaygannejad; Serge Brand
Journal:  J Clin Med       Date:  2022-01-29       Impact factor: 4.241

2.  Whole-Exome Sequencing Reveals a Missense Variant c.1612C>T (p.Arg538Cys) in the BTD Gene Leading to Neuromyelitis Optica Spectrum Disorder in Saudi Families.

Authors:  Muhammad Imran Naseer; Peter Natesan Pushparaj; Angham Abdulrahman Abdulkareem; Osama Y Muthaffar
Journal:  Front Pediatr       Date:  2022-02-21       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.